Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03532451 |
| Title | Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807) |
| Acronym | PrE0807 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | PrECOG, LLC. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | United States | Details | |
| Montefiore Medical Center | Bronx | New York | 10461 | United States | Details | |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States | Details | |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | United States | Details | |
| Oregon Health & Science University | Portland | Oregon | 97239 | United States | Details | |
| University of TX Southwestern | Dallas | Texas | 75390 | United States | Details | |
| University of Virginia | Charlottesville | Virginia | 22903 | United States | Details | |
| University of Washington | Seattle | Washington | 98109 | United States | Details |